Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. reported that on August 22, 2025 it prepaid in full all outstanding obligations under its Credit Agreement with Hayfin Services LLP, then terminated the facility. The prepayment covered an aggregate principal amount of $60.1 million plus $1.0 million of accrued interest. The company states that it did not incur any exit or prepayment fees in connection with closing out this debt arrangement.
The Credit Agreement, originally dated June 14, 2024 and amended January 24, 2025, was a material financing arrangement for the company. Heartflow refers investors to the liquidity and capital resources section of its prior Form S-1 registration statement for a fuller description of the original terms.
HealthCor-related entities reported acquisitions of Heartflow, Inc. (HTFL) securities on 08/11/2025 recorded in a joint Form 4 filing. The filing shows HealthCor Partners Fund, L.P. acquired 1,248,939 common shares (as-converted from Series C preferred), HealthCor Partners Fund II, L.P. acquired 833,075 common shares (as-converted), and HCPCIV 1, LLC acquired 4,615,542 common shares (as-converted). Multiple preferred series and a convertible promissory note were reported as automatically converted into specified common share amounts immediately prior to Heartflow's IPO closing. Reporting signatures are dated 08/22/2025.
HealthCor-affiliated entities reported initial beneficial ownership in Heartflow, Inc. (HTFL). Multiple HealthCor funds and affiliates each hold various series of convertible preferred stock and a convertible promissory note that will convert into Heartflow common stock upon the closing of Heartflow's initial public offering. Conversion ratios after a 1-for-2.92 reverse split are disclosed for Series C, D, E, F and F-1 preferred stock and a conversion mechanism is disclosed for the promissory note (80% of IPO price, subject to a $2.0 billion valuation cap). HealthCor Partners Management, L.P. is the investment manager with voting and investment discretion and disclaims direct beneficial ownership except for pecuniary interests.
Bain Capital Life Sciences Investors, LLC and affiliated entities reported conversions of pre-IPO securities into Heartflow, Inc. common stock on 08/11/2025. The Issuer's Series F Preferred Stock converted on a 0.342466:1 basis into 12,014,234 common shares. A Subordinated Convertible Promissory Note with principal $6,595,648.51 converted into 433,924 common shares at a stated conversion price of $15.2. Following these transactions, the reporting group beneficially owned 12,448,158 common shares. The filings identify the reporting persons as directors and 10% owners and disclose an indirect ownership chain through several Bain Capital entities, with customary disclaimers about beneficial ownership.